ArticlePediatric nephrology (Berlin, Germany)2026
Relapsing childhood steroid sensitive nephrotic syndrome: what determines eventual remission?
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood idiopathic nephrotic syndrome (INS) responds to corticosteroids (CS), but tends to relapse, often requiring steroid sparing agents (SSA). Long standing treatment free remission (LTFR) evolves in most cases, but whether this is related to puberty or disease length is unknown.
methodsWe retrospectively analyzed the computerized database of Israel's largest health maintenance organization. Children with a new INS diagnosis between 2000-2010 were divided into 2 groups according to INS presentation age. Disease length was determined based on CS or SSA use. Children with disease shorter than 1 year or those not reaching LTFR, defined as more than 3 years from last purchase, were excluded.
resultsOut of 1,669,977 eligible children, 608 were diagnosed with INS, 524 relapsed, 174 were excluded, leaving 350 for analysis: 272 (77.7%) and 78 (22.2%) presented between 2-6.9 and 7-9.9 years, respectively. There was no difference in the need for SSA, time to SSA initiation and drug purchase count between the groups. After 15.5 ± 5.1 years of follow up, time until LTFR was longer in the older group (5.4 ± 4 vs. 7.1 ± 5.1 years, p = 0.002), without correlation between INS onset age and disease length. Many patients, especially in the older group, still relapsed beyond Tanner stage 3's 97th percentile age (age 14 years) (14.7% vs. 51.3%, p < 0.001), irrelevant of sex.
conclusionsIn this population-based study LTFR occurred in many cases well beyond puberty, in both groups, favoring the role for disease length on LTFR, probably due to maturational immune system changes.
Indexed as
Identifiers
42141295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.